Intracerebral haemorrhage. Intracerebral haemorrhage in hemisphere, unspecified
Conditions
Interventions
Intervention 1: Memantine , 10 mg oral pill daily for the first month and 20mg forthe next two months. Intervention 2: Placebo, 10 mg oral pill daily for the first month and 20mg for the next 2 mont
Treatment - Drugs
Placebo
Memantine , 10 mg oral pill daily for the first month and 20mg forthe next two months
Placebo, 10 mg oral pill daily for the first month and 20mg for the next 2 months
Sponsors
Deputy of research, Guilan University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The inclusion criteria: 1. Patients with the diagnosis of first ever, spontaneous, non-traumatic supratentorial ICH confirmed by a clinical examination and radiological findings 2. Admission NIHSS 5 7. Admission hematoma volume <30 cc Patients who will not include: 1.Those with previous or concomitant ischemic stroke 2.Those with other systemic disease including liver or kidney failure 3. Those who have pace maker, or suffer from severe neuropathy, systemic vascular disease or major affective disorders. 4. Those with a positive history of severe disability due to neurological or non-neurological causes 5.Those with a previous history of ICH, myocardial infarction or ischemic stroke 6. Those who abuse alcohol 7. Those with confirmed diagnosis of cognitive disorders based on DSM-IV criteria for dementia or IQCODE questionnaire 8. Those with ICH secondary to brain trauma or rupture of brain aneurysm 9. Those with a history of using anticoagulant drugs, antiplatelet drugs and NSAIDs. 10. Pregnant patients 11. Those with concomitant Intraventricular hemorrhage (IVH) 12.Deep coma Exclusion criteria: 1. Refusal to continue with the study 2. The occurrence of serious adverse drug affects at any time during the study. 3. Alcohol abuse during the study period
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality. Timepoint: During the three-month follow-up period. Method of measurement: Mortality rate.;Functional recovery. Timepoint: On admission, 7th day, and on discharge. Method of measurement: National Institute of Health Stroke Scale(NIHSS).;Motor recovery. Timepoint: On admission, 7th day, on discharge, and 3 month later. Method of measurement: Fugl-Meyer (FM).;Disability. Timepoint: On admission, 7th day, on discharge, and 3 month later. Method of measurement: modified Rankin Scale(mRS).;Performance in basic Activities of Daily Living. Timepoint: On admission, 7th day, on discharge, and 3 month later. Method of measurement: Barthel index (BI).;Level of consciousness. Timepoint: On admission, 7th day, and on discharge. Method of measurement: Glosgow coma scale (GCS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in the size of hematoma. Timepoint: On admission, 72 hours later, and 7th day. Method of measurement: Based on the findings of CT scan.;Changes in the size of perihematomal edema. Timepoint: On admission, 72 hours later, and 7th day. Method of measurement: Based on the findings of CT scan. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mohadeseh Hajinoori
Guilan University of Medical Science
Outcome results
None listed